Answers are grounded in this paper and cite their sources.
BACKGROUND AND AIMS: Decompensated cirrhosis has traditionally been considered irreversible. However, evidence shows that patients who achieve control or cure of the underlying liver disease aetiology can experience substantial clinical improvement, termed 'cirrhosis recompensation', formally defined by Baveno VII and further modified during Baveno VIII. This review synthesizes current knowledge on the pathophysiology, predictors, aetiology-specific outcomes, clinical implications and trial design considerations relevant to recompensation. METHODS: We conducted a narrative review synthesizing data across six domains: pathophysiology of decompensation and recompensation; predictors of recompensation; prevalence and prognostic impact by aetiology; unresolved controversies in definition; clinical implications, including medication de-escalation, transplant delisting and hepatocellular carcinoma (HCC) surveillance; and methodological considerations for clinical trial design. RESULTS: Recompensation occurs in an estimated 35% of patients with decompensated cirrhosis and is associated with reduced liver-related mortality, though rates vary substantially by aetiology. Proposed mechanisms include reduced portal pressure, restored gut barrier integrity and possible fibrosis regression. Despite improved outcomes, HCC risk and, in some patients, portal hypertension persist, warranting ongoing surveillance. Some aspects of the definition remain unresolved, including uncertain applicability to etiologies lacking a clear curative therapy. As a trial endpoint, recompensation is clinically meaningful and sufficiently prevalent, though it requires appropriate handling of competing risks and consideration of multi-state modelling and outcome-ranking approaches. CONCLUSIONS: Cirrhosis recompensation represents a paradigm shift in the understanding and management of decompensated liver disease. Future work should focus on validating recompensation criteria across diverse etiologies, clarifying underlying mechanisms and durability and establishing standardized methodological frameworks for incorporating recompensation into clinical trial design.
No takes yet. Share an insight, caveat, or question.
Rabiee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: